In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.

Inari Medical, Inc. NARI is well-poised for ... The company is currently engaged in the limited market release of Venacore, the second purpose-built tool within the CBD toolkit, expanding NARI ...

Inari Medical, Inc. NARI is well-poised for growth on the back ... The company is currently engaged in the limited market release of Venacore, the second purpose-built tool within the CBD toolkit, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Analysts' ratings for Inari Medical NARI over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table encapsulates their recent ratings, offering a glimpse ...